Lipigon Pharmaceuticals AB Stock

Equities

LPGO

SE0015382072

Pharmaceuticals

Market Closed - Nasdaq Stockholm 10:21:41 2024-05-31 am EDT 5-day change 1st Jan Change
0.2915 SEK -2.83% Intraday chart for Lipigon Pharmaceuticals AB +1.92% -32.37%
Sales 2024 * 14.8M 1.41M Sales 2025 * 26.8M 2.55M Capitalization 36.85M 3.5M
Net income 2024 * -18M -1.71M Net income 2025 * -25M -2.38M EV / Sales 2024 * 1.17 x
Net cash position 2024 * 19.6M 1.86M Net cash position 2025 * - 0 EV / Sales 2025 * 1.38 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 6
Yield 2024 *
-
Yield 2025 *
-
Free-Float 70.42%
More Fundamentals * Assessed data
Dynamic Chart
Lipigon Pharmaceuticals AB and Leaderna Therapeutics Collaboration on Lipisense® Shows Good Progress CI
Lipigon Pharmaceuticals AB Collaborates with University of Washington on Lung Damage Project CI
Lipigon Collaborates with University of Washington on Lung Damage Project CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Lipigon Pharmaceuticals’ Lipisense Gets Swedish Regulators' Nod for Mid-stage Study MT
The Swedish Medical Products Agency Approves Lipigon's Phase II Study with Lipisense CI
Lipigon Pharmaceuticals AB Announces Lipisense Progressing to Phase II Trials CI
Lipigon Pharmaceuticals AB Reports A Statically Confirms reduction of target protein ANGPTL4 after repeate treatment with Lipisense ® CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Lipigon Applies for Clinical Trial Phase II for Lipisense CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Lipigon Pharmaceuticals AB Announces Positive Safety Results and Encouraging Target Engagement Data from the Phase I Lipisense Trial CI
Lipigon Pharmaceuticals Surges 40% on Lipisense Development, Licensing Deal in China MT
Lipigon Announces Development and License Agreement with Leaderna Therapeutics Ltd CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
1 day-2.83%
1 week+1.92%
1 month-14.26%
3 months-28.20%
6 months-17.19%
Current year-32.37%
More quotes
1 week
0.24
Extreme 0.24
0.32
1 month
0.24
Extreme 0.24
0.38
Current year
0.24
Extreme 0.24
0.54
1 year
0.24
Extreme 0.24
0.82
3 years
0.24
Extreme 0.24
10.50
5 years
0.24
Extreme 0.24
12.00
10 years
0.24
Extreme 0.24
12.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 10-04-05
Chairman 67 11-12-31
Director of Finance/CFO 54 22-12-31
Members of the board TitleAgeSince
Chairman 67 11-12-31
Director/Board Member 52 20-12-31
Director/Board Member 64 22-12-31
More insiders
Date Price Change Volume
24-05-31 0.2915 -2.83% 131,499
24-05-30 0.3 +0.17% 614,237
24-05-29 0.2995 +4.54% 928,159
24-05-28 0.2865 -2.39% 1,078,907
24-05-27 0.2935 +2.62% 560,562

Delayed Quote Nasdaq Stockholm, May 31, 2024 at 10:21 am EDT

More quotes
Lipigon Pharmaceuticals AB is a Sweden-based project portfolio company. Lipigon's business concept is to develop medicines with new, unique mechanisms of action (so-called first-in-class) for diseases that lack adequate treatment. The Company develops medicines with a focus on diseases where the body's ability to handle fats is disturbed, so-called lipid-related diseases, and where there are unmet medical needs. Initially, the Company's development focuses on advanced diseases or genetically defined patient segments where it is possible to identify treatment effects early in the clinical development. It creates the conditions for studies with fewer patients and a shorter path to market approval and thus a reduced development risk.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Chiffre d''affaires - Rate of surprise